Generally, cancer therapy can be categorized based on its target on one or more hallmark of cancer capabilities, which include sustaining proliferative signaling (EGFR inhibitors), evading growth suppressors (CDK inhibitors), resisting cell death (proapoptotic BH3 mimetics), enabling replicative immortality (telomerase inhibitors), inducing angiogenesis (inhibitors of VEGF signaling), and activating invasion and metastasis (inhibitors of HGF/c-Met) [6]. The gene discussed is MET; the disease is cancer.